OncoMatch/Clinical Trials/NCT07337460
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
Is NCT07337460 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Icaritin Soft Capsules and mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil for hepatocellular carcinoma (hcc).
Treatment: Icaritin Soft Capsules and mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil — This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with Modified Folinic acid, Fluorouracil, and Oxaliplatin (mFOLFOX) in hepatocellular carcinoma (HCC) with high-risk recurrence factors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Grade: iiiiv (edmondson)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical surgery
Patients who underwent radical surgery within the first 8 weeks and meet the following criteria: a. Histologically confirmed negative surgical margins (R0) for radical surgery
Cannot have received: adjuvant therapy (e.g. TACE)
Patients who have undergone adjuvant therapies such as transarterial chemoembolization (TACE) after radical surgery
Cannot have received: Chinese herbal medicine or Chinese patent medicine with antitumor indications or immunomodulatory drugs (including systemic use of thymosin, interferon, etc.)
Received Chinese herbal medicine or Chinese patent medicine with antitumor indications or immunomodulatory drugs (including systemic use of thymosin, interferon, etc.) within 14 days prior to enrollment
Cannot have received: other drug clinical trials
Participation in other drug clinical trials within 4 weeks prior to enrollment
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L; platelet count ≥80×10⁹/L; hemoglobin ≥90 g/L
Kidney function
Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance (CCr) ≥45 mL/min (Cockcroft-Gault formula) for subjects with Cr>1.5×ULN
Liver function
Serum totalbilirubin (TBIL) ≤2×ULN, or direct bilirubin ≤ULN for subjects with TBIL>2×ULN; ALT and AST ≤3×ULN; serum albumin ≥28 g/L; Child-Pugh classification grade B or C excluded
The patient must have adequate organ and bone marrow function, with laboratory test values meeting the following criteria: ... Child-Pugh classification grade B or C, or a history of hepatic encephalopathy [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify